1	Article Summary Line: High nasopharyngeal viral load around the onset may contributes to
2	secondary transmission of COVID-19.
3	
4	Running title: Viral load and secondary transmission in COVID-19
5	
6	Keywords: viral load, secondary transmission, COVID-19
7	
8	Title
9	Viral load dynamics in transmissible symptomatic patients with COVID-19
10	
11	Authors:
12	Hitoshi Kawasuji, Yusuke Takegoshi, Makito Kaneda, Akitoshi Ueno, Yuki Miyajima,
13	Koyomi Kawago, Yasutaka Fukui, Yoshihiko Yoshida, Miyuki Kimura, Hiroshi Yamada,
14	Ippei Sakamaki, Hideki Tani, Yoshitomo Morinaga, and Yoshihiro Yamamoto
15	
16	Author affiliation:
17	Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama,
18	Japan
19	
20	Abstract
21	To investigate the relationship between viral load and secondary transmission in novel
22	coronavirus disease 2019 (COVID-19), we reviewed epidemiological and clinical data
23	obtained from immunocompetent laboratory-confirmed patients with COVID-19 at Toyama
24	University Hospital. In total, 28 patients were included in the analysis. Median viral load at
25	the initial sample collection was significantly higher in adults than in children and in

symptomatic than in asymptomatic patients. Among symptomatic patients, non-linear regression models showed that the estimated viral load at onset was higher in the index (patients who transmitted the disease to at least one other patient) than in the non-index patients (patients who were not the cause of secondary transmission; median [95% confidence interval]: 6.6 [5.2–8.2] vs. 3.1 [1.5–4.8] log copies/µL, respectively). High nasopharyngeal viral loads around onset may contribute to secondary transmission of COVID-19.

33 Introduction

34 Coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute 35 respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic, and 36 currently threatens human health and lifestyles. Thus, it is important to gain an accurate 37 understanding of the risk of infection with SARS-CoV-2. Generally, the risk of microbial 38 human-to-human transmission is dependent on the duration of the highly-infectious phase 39 and the number of virions contained in air particulates such as droplets and aerosols. 40 However, as it is a new disease, little is yet known about COVID-19 and the risk of infection 41 in various situations.

The viral load of SARS-CoV-2 peaks around the time of symptom onset, followed by a gradual decrease to a low level after about 10 days (*1*,2). Regarding the period of high infectiousness, a recent study reported that exposure to an index case within 5 days of symptom onset confers a high risk of secondary transmission (*3*). The high transmissibility around symptom onset gradually decreases, consistent with the dynamical pattern of viral shedding (*4*).

In addition, viral load can be associated with infectiousness, especially in the acute phase of COVID-19. However, little information is available on the relationship between nasopharyngeal viral load and secondary transmission. Therefore, in this study, we reviewed patients with COVID-19, including family clusters, and conducted follow-up interviews to investigate the relationship between viral load and secondary infection.

53 Materials and methods

54 Epidemiological and clinical data were obtained from immunocompetent 55 laboratory-confirmed patients with COVID-19 who were admitted to and/or from whom viral 56 loads were measured at Toyama University Hospital. Index patients and those with secondary 57 transmission were estimated based on serial intervals in the family clusters, and

epidemiological and clinical data, including the number of secondary patients in health care,
household, or other social settings, were investigated through structured telephone interviews.
The study was performed in conformity with the Helsinki Declaration, after approval by the
Ethical Review Board of University of Toyama (approval number: R2019167). Written
informed consent was obtained from all patients.

63 The patients were divided into two groups: those who subsequently transmitted the
64 disease to at least one other patient (index patients), and those who did not (non-index
65 patients).

For each patient, the following data were retrieved from medical charts and structured
telephone interview sheets: demographics, clinical presentation, date of symptom onset, date
of initial sample collection, need for supplemental oxygen (moderate) and/or mechanical
ventilation (severe), and dates of the first negative quantitative reverse transcription
polymerase chain reaction (RT-qPCR) test result and hospital discharge.

71 Nasal swab specimens were pretreated with 500 µL of Sputazyme (Kyokuto 72 Pharmaceutical, Tokyo, Japan). After centrifugation at $20,000 \times g$ for 30 min at 4°C, the 73 supernatant was used for RNA extraction. A total of 60 µL of RNA solution was obtained 74 from 140 µL of the supernatant using the QIAamp ViralRNA Mini Kit (QIAGEN, Hilden, 75 Germany) or Nippongene Isospin RNA Virus (Nippongene, Tokyo, Japan) according to the 76 manufacturer's instructions. The viral loads of SARS-CoV-2 were quantified based on an 77 N2-gene-specific primer/probe set by RT-qPCR according to the Japan National Institute of 78 Infectious Diseases protocol (5). The quality of quantification was controlled by AcroMetrix 79 Coronavirus 2019 (COVID-19) RNA Control (Thermo Fisher Scientific, Fremont, CA). The 80 detection limit was approximately 0.4 copies/ μ L (2 copies/5 μ L).

81 Continuous and categorical variables were presented as the median (interquartile 82 range [IQR]) and n (%), respectively. We used the Mann–Whitney U test, χ^2 test, or Fisher's

exact test to compare differences between the index and non-index patients where appropriate.
Data were analyzed using JMP Pro version 14.2.0 software (SAS Institute Inc., Cary, NC,
USA). The viral load time courses were assessed using nonlinear regression employing a
standard one-phase decay model in Prism version 8.4.2 (GraphPad Software Inc., San Diego,
CA, USA).

88 **Results**

89 Among the 28 patients (median age, 45.5 years) with laboratory-confirmed 90 COVID-19, 15 (53.6%) were male, 21 (75.0%) were adults (18 years or older), and 10 91 (35.7%) were asymptomatic (Table 1). Among their 105 close contacts, 14 paired 92 index-secondary cases were found. Fourteen (50.0%) were index patients within 11 family 93 clusters, 10 (35.7%) were secondary transmission patients without further spreading within 94 seven family clusters, and the remaining four (14.3%) were sporadic cases. Of the 18 95 symptomatic patients, the numbers of mild, moderate, and severe cases were 12, 5, and 1, 96 respectively.

97 A total of 89 nasopharyngeal swabs were collected from the 28 patients from 2 to 36 98 days after onset. The median (IQR) time at initial sample collection was 6 (2.8–9) days after 99 symptom onset. The median viral load at the initial sample collection was significantly higher 100 in adults than in children (p=0.02, 2.3 vs. 0.9 log copies/ μ L, respectively); however, viral 101 loads during follow-up were not significantly different between the two groups (p=0.89). In 102 addition, the median viral load at initial sample collection was significantly higher in 103 symptomatic than in asymptomatic patients (p<0.01, 2.8 vs. 0.9 log copies/ μ L, respectively).

Next, the viral load in symptomatic patients was compared between the index and non-index patients (Table 2). Viral loads peaked soon after symptom onset, and then gradually decreased toward the detection limit (Figure 1A). The time to viral clearance from onset in the index patients was 21 (15–31) days (median [range]), and no significant

difference was found between the index and non-index patients (p=0.09, 10 [9–26] days,median [range]).

Among the symptomatic patients, the nasopharyngeal viral loads at the initial sample collection were not significantly different between the index and non-index patients (p=0.15, median [range]: 3.1 [1.6 to 5.2] vs. 1.9 [-0.4 to 4.6] log copies/ μ L, respectively). However, nonlinear regression models using all the data from the index or non-index patients showed that the viral load of the index patients at onset was higher than that of the non-index patients (median [95% confidence interval]: 6.6 [5.2 to 8.2] vs. 3.1 [1.5 to 4.8] log copies/ μ L, respectively), and this trend continued until 10 days after onset (Figure 1B).

117 Discussion

In this study, we analyzed viral loads in nasopharyngeal swabs obtained from 18
symptomatic and 10 asymptomatic patients with laboratory-confirmed COVID-19 to assess
the relationship between viral load and secondary transmission.

121 Although a recent study suggested that the viral load detected in asymptomatic 122 patients was similar to that in symptomatic patients (2), in this study, the viral load at the time 123 of initial sample collection was significantly higher in symptomatic than in asymptomatic 124 patients. Furthermore, among the symptomatic patients, the viral loads in the index patients 125 were significantly higher than those in the non-index patients at about 5 days after onset. 126 Further studies are needed to confirm these results, as this study only involved a small 127 number of patients. However, it is plausible that high nasopharyngeal viral loads contribute to 128 secondary transmission of COVID-19. To our knowledge, no previous study has assessed the 129 relationship between viral load and secondary transmission. Among the asymptomatic 130 carriers, it was difficult to determine whether the viral load could impact transmission 131 because no carrier had a high viral load.

132 After symptom onset, the viral load decreased monotonically. The median time to 133 clearance of the virus was similar to that in a previous report, in which virus was detected for 134 a median of 20 days (up to 37 days among survivors) after symptom onset (6). However, the 135 median time did not differ between the index and non-index patients. These findings imply 136 that viral clearance is independent of the initial virus load, but may be regulated by the host 137 immune response. In most patients, the virus was detected for about 3 weeks; however, when 138 the risk of transmission disappears remains unclear. A previous report demonstrated that 139 infectiousness may decline at 8 days after symptom onset (7). Although the relationship 140 between viral load and the infectiousness of COVID-19 remains unknown (8), the present 141 study provides insight into the viral load threshold associated with infectivity.

142 This study has several limitations inherent to the small sample size and potential for 143 confounding viral load and clinical conditions that cannot be excluded. The date of symptom 144 onset and disappearance and information on disease transmission relied on self-reported 145 information from the patients and their families, as well as information from public health 146 centers, which could potentially lead to missing some cases of secondary transmission. In 147 addition, the viral load dynamics were based on data from patients who received treatment, 148 including combinations of antivirals and antibiotics, which could have modified the patterns 149 of the viral load dynamics.

In conclusion, the results of this study suggest that a high nasopharyngeal viral load may contribute to the secondary transmission of COVID-19. In addition, the viral load may help explain why transmission is observed in some instances, but not in others, especially among household contacts. Although RT-qPCR does not distinguish between infectious virus and noninfectious nucleic acid, our findings may lead to the establishment of a viral load threshold to clarify COVID-19 disease transmission and infectivity.

156

157 Acknowledgn	nent
-----------------	------

158 We thank Ai Kakumoto for supporting PCR.

159

TOU AUDIOL DI	160	Author	Bio
---------------	-----	--------	-----

161 H. Kawasuji is a clinical fellow of Toyama University Hospital. He is also a

162 PhD-course student and has one publication about methicillin-resistant Staphylococcus

163 *aureus* bacteremia as first author.

164

165 Conflict of interest

166 We declare that we have no conflict of interest.

167

168 Funding

- 169 This research did not receive any specific grant from funding agencies in the public,
- 170 commercial, or not-for-profit sectors.

171

173 **References:**

- PanY, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical
 samples. Lancet Infect Dis. 2020;20(4):411-2.
- 2. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load
 in Upper Respiratory Specimens of Infected Patients. N Engl J Med.
- 178 2020;382(12):1177-9.
- Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact Tracing
 Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different
 Exposure Periods Before and After Symptom Onset. JAMA Intern Med.
 2020;e202020; Epub ahead of print. doi: 10.1001/jamainternmed.2020.2020.
- 4. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
 shedding and transmissibility of COVID-19. Nat Med. 2020;26:672-5.
- 5. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan. Jpn
 J Infect Dis. 2020;10.7883/yoken.JJID.2020.061; Epub ahead of print. doi:10.7883/yoken.JJID.2020.061
- 189 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
 190 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
 191 study. Lancet. 2020;395(10229):1054-62.
- 192 7. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
 193 Virological assessment of hospitalized patients with COVID-2019. Nature.
 194 2020;581(7809):465-9.
- 195 8. Atkinson B, Petersen E. SARS-CoV-2 shedding and infectivity. Lancet.
 196 2020;395(10233):1339-40.

- 197 Address for correspondence: Yoshihiro Yamamoto, Department of Clinical Infectious
- 198 Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences,
- 199 2630 Sugitani, Toyama 930-0194, Japan; TEL: +81-76-434-7245; FAX:
- +81-76-434-5018; e-mail: yamamoto@med.u-toyama.ac.jp

Characteristics	Study population	203
Age, median, y	45.5	204
0–17, n (%)	7 (25.0)	204
18–64, n (%)	14 (50.0)	
≥65, n (%)	7 (25.0)	
Sex		
Male, n (%)	15 (53.6)	
Situation, n (%)		
Index	14 (50.0)	
Secondary	10 (35.7)	
Sporadic	4 (14.3)	
Presence of symptoms, n (%)		
Asymptomatic	10 (35.7)	
Symptomatic	18 (64.3)	
Mild	12 (42.9)	
Moderate	5 (17.9)	
Severe	1 (3.6)	

202 **Table 1.** Basic characteristics of the patients.

Index patients, Non-index patients,		P-value	
n = 11	n = 7	F-value	
6 (2 to 12)	4 (-1 to 10)	0.52	
3.1 (1.6 to 5.2)	1.9 (-0.4 to 4.6)	0.15	
4.9 (4.4 to 5.2)	3.0 (0.7 to 4.6)	0.11	
2.3 (1.6 to 4.9)	0.7 (-0.4 to 3.1)	0.17	
21 (15 to 31)	11 (9 to 26)	0.09	
	n = 11 6 (2 to 12) 3.1 (1.6 to 5.2) 4.9 (4.4 to 5.2) 2.3 (1.6 to 4.9) 21 (15 to 31)	Index patients,Non-index patients, $n = 11$ $n = 7$ $6 (2 \text{ to } 12)$ $4 (-1 \text{ to } 10)$ $3.1 (1.6 \text{ to } 5.2)$ $1.9 (-0.4 \text{ to } 4.6)$ $4.9 (4.4 \text{ to } 5.2)$ $3.0 (0.7 \text{ to } 4.6)$ $2.3 (1.6 \text{ to } 4.9)$ $0.7 (-0.4 \text{ to } 3.1)$ $21 (15 \text{ to } 31)$ $11 (9 \text{ to } 26)$	

205 Table 2. Summary of viral load in the index and non-index patients.

207 Figure legend

- **208** Figure 1. Trends in viral loads in the symptomatic patients.
- 209 (A) Viral load time courses of index (red) and non-index patients (blue). (B) Nonlinear
- 210 regression models of index (red) and non-index patients (blue). The models were calculated
- 211 by using all the data of the index or non-index patients. When no virus was detected, the data
- 212 were hypothetically plotted as -0.5 log copies/µL. Solid curves are best-fit models and dotted
- 213 lines indicate the 95% confidence interval of each model.



Figure 1B

